Eclipsebio Acquires Terrain Bio, Forging an AI-Powered RNA Drug Platform

SAN DIEGO, CA – January 26, 2026 – In a strategic move set to reshape the landscape of RNA therapeutic development, Eclipse Bioinnovations, Inc. today announced its acquisition of Terrain Bio, a techbio startup specializing in AI-driven RNA design. The deal combines Eclipsebio's leadership in high-resolution sequencing analytics with Terrain Bio's advanced machine learning capabilities, creating a powerful, end-to-end platform to design, manufacture, and validate next-generation RNA medicines.

The acquisition signals a significant consolidation in the burgeoning biotech sector, where the race to leverage artificial intelligence is reaching a fever pitch. By integrating Terrain Bio's design and manufacturing prowess, Eclipsebio aims to offer a unified "Design, Make, Test" solution that could dramatically shorten development timelines and increase the success rate of bringing novel RNA therapies from the lab to the clinic.

A New Paradigm for RNA Development

The promise of RNA therapeutics—from mRNA vaccines to targeted cancer treatments—has ignited the biopharmaceutical industry. However, the path from concept to cure is fraught with challenges. Designing stable, effective, and manufacturable RNA sequences is a complex puzzle, often requiring lengthy and expensive trial-and-error cycles.

Eclipsebio's acquisition directly targets this bottleneck. The combined platform aims to create a closed-loop system where computational design is seamlessly connected with real-world experimental feedback. Terrain Bio, which launched from stealth in 2025 with $9 million in seed funding from prominent investors, developed machine learning models that optimize RNA sequences for expression and durability. Critically, it paired this AI with an R&D-scale manufacturing platform, enabling rapid testing of its computationally designed constructs.

By merging these capabilities with Eclipsebio's established sequencing platforms, such as eMERGE™ and eVERSE™, the new entity can offer a uniquely comprehensive service. The eMERGE™ platform provides deep insights into a therapeutic's translation efficiency and structure, while the eVERSE™ portfolio offers vast, high-quality, "AI-ready" datasets essential for training more sophisticated machine learning models.

“This acquisition meaningfully advances our vision for Eclipsebio,” said Peter Chu, CEO of Eclipsebio, in the official announcement. “Terrain Bio’s proven AI design capabilities strongly complement our sequencing-first analytics, allowing us to support RNA drug developers earlier in development while continuing to deliver the deep sequencing-based validation our partners rely on for confident decision-making.”

This integration means that an RNA sequence designed by the AI can be rapidly manufactured and then deeply analyzed using Eclipsebio's sequencing technology. The data from that analysis—on everything from structure and impurities to translation efficiency—is then fed back into the AI models, creating a cycle of continuous improvement. This "active learning" approach is expected to generate better therapeutic candidates with each iteration.

A Power Play in a Competitive Field

The move positions Eclipsebio as a formidable competitor in a market crowded with both established pharmaceutical giants and nimble AI-focused startups. Companies like Moderna have already demonstrated the power of AI in accelerating vaccine development, while players like Deep Genomics, Anima Biotech, and Shape Therapeutics are leveraging proprietary AI platforms to discover and design novel RNA-based treatments.

What sets the combined Eclipsebio-Terrain Bio entity apart is the completeness of its proposed solution. While many companies specialize in either AI-driven design or downstream analytics, few offer a single, integrated platform that spans the entire preclinical workflow. This "one-stop-shop" approach could be highly attractive to biopharma partners looking to streamline their R&D and de-risk their drug candidates early.

“Eclipsebio’s deep expertise in sequencing-based validation and curated data repository makes this combination uniquely powerful,” stated Chetan Tadvalkar, CEO of Terrain Bio. “Together, we close the gap between computational design and real-world experimental validation, helping RNA therapeutics reach the clinic faster and with greater confidence.”

The financial backing of both companies prior to the acquisition underscores the perceived value of their respective technologies. Eclipsebio secured an oversubscribed $14 million Series A round in 2022, co-led by Alexandria Venture Investments and iGlobe, with the explicit goal of expanding its RNA genomics products and fueling new AI algorithms. Terrain Bio's successful seed round attracted notable biotech leaders and venture firms, validating its approach to integrating AI design with rapid manufacturing. This merger combines two well-funded, technologically validated entities into a more powerful whole.

Accelerating the Path from Code to Cure

The ultimate impact of this acquisition may be measured in the speed at which new treatments become available to patients. The traditional drug development pipeline is notoriously slow and expensive, with high failure rates. By optimizing the preclinical phase, Eclipsebio's integrated platform has the potential to deliver significant efficiency gains.

Terrain Bio had previously claimed its technology could accelerate RNA design and build cycles by a factor of three to six compared to industry standards. By integrating this speed with Eclipsebio's deep analytical validation, the combined platform promises to help drug developers identify and advance the most promising candidates with greater certainty. This could reduce the immense costs associated with advancing suboptimal candidates that ultimately fail in later-stage trials.

The benefits extend across the spectrum of RNA therapeutics. For developers of personalized cancer vaccines, which require the rapid design and production of patient-specific mRNA, such a platform could be transformative. For those working on treatments for rare genetic disorders, the ability to iteratively design and test highly specific RNA molecules more efficiently could unlock new therapeutic possibilities.

The combined platform will enable partners to not only design optimized RNA constructs but also gain high-resolution analytics on their structure and function, along with actionable insights into manufacturing robustness. This holistic view supports a "quality-by-design" approach, ensuring that potential therapies are built on a solid foundation from the very beginning. As the industry continues to harness the full potential of RNA, integrated platforms that bridge the gap between digital design and biological reality will be crucial for turning scientific promise into patient cures.